Compare Bristol-Myers Squibb Co (BMY) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Sprott Uranium Miners ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.83 (market cap $116.30B), while Sprott Uranium Miners ETF trades at $50.81. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Sprott Uranium Miners ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| BMY | URNM | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $83.99 |
52-Week Low | $42.60 | $44.14 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
URNM trades at $50.21, down 5.78% over 24 hours amid bearish technical signals, with moving averages indicating strong selling pressure. The uranium ETF faces volatility despite positive sector narratives around AI-driven power demand. Financial ratios are unavailable as this is a fund holding mining equities rather than an operating company with traditional financial statements.
The long-term uranium thesis remains supported by nuclear energy's role in AI infrastructure, but near-term price action shows weakness. Concentration in miners creates higher volatility versus diversified nuclear ETFs. Key risks include uranium spot price fluctuations and miner operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
